UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

---

 

FORM 8-K

---

 

CURRENT REPORT

 

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): February 24, 2017

 

PHARMERICA CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

 

---

 

 

(502) 627-7000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( see  General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

---

Item 2.02

Results of Operations and Financial Condition.

On February 24, 2017, PharMerica Corporation (the “Company”) issued a press release announcing results of operations for the fourth quarter ended December 31, 2016, a copy of which is attached as Exhibit 99.1.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

99.1	Press Release of PharMerica Corporation dated February 24, 2017.

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Exhibit Index

 

 

---